Unit information prior for adaptive information borrowing from multiple historical datasets
暂无分享,去创建一个
[1] Eran Segal,et al. Overlapping codes within protein-coding sequences. , 2010, Genome research.
[2] P. Müller,et al. Determining the Effective Sample Size of a Parametric Prior , 2008, Biometrics.
[3] S. Gauthier,et al. Synthesis and Comparison of the Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s Disease , 2013, CNS Drugs.
[4] Steven G Potkin,et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[5] L. Wasserman,et al. A Reference Bayesian Test for Nested Hypotheses and its Relationship to the Schwarz Criterion , 1995 .
[6] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[7] J. Olin,et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. , 2008, Current Alzheimer research.
[8] D. Spiegelhalter,et al. Summarizing historical information on controls in clinical trials , 2010, Clinical trials.
[9] Anthony O'Hagan,et al. Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.
[10] Michael Branson,et al. A note on the power prior , 2009, Statistics in medicine.
[11] Emmanuel Lesaffre,et al. Modified power prior with multiple historical trials for binary endpoints , 2018, Statistics in medicine.
[12] Tim Friede,et al. Dynamically borrowing strength from another study through shrinkage estimation , 2018, Statistical methods in medical research.
[13] Se-Ran Jun,et al. Alignment-free genome comparison with feature frequency profiles (FFP) and optimal resolutions , 2009, Proceedings of the National Academy of Sciences.
[14] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[15] Ying Cheng,et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[16] Rachelle Doody,et al. Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.
[17] Keying Ye,et al. Evaluating water quality using power priors to incorporate historical information , 2006 .
[18] J. Kornhuber,et al. Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.
[19] Yoshua Bengio,et al. Generative Adversarial Nets , 2014, NIPS.
[20] M. Mega,et al. The Neuropsychiatric Inventory , 1994, Neurology.
[21] M. Mega,et al. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. , 1999, Archives of neurology.
[22] S. Bakchine,et al. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. , 2007, Journal of Alzheimer's disease : JAD.
[23] Bradley P Carlin,et al. Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials , 2011, Biometrics.
[24] Satoshi Morita,et al. Prior Effective Sample Size in Conditionally Independent Hierarchical Models. , 2012, Bayesian analysis.
[25] Leonhard Held,et al. Power priors based on multiple historical studies for binary outcomes , 2017, Biometrical journal. Biometrische Zeitschrift.
[26] Tomoyuki Kakizume,et al. Applying Meta-Analytic-Predictive Priors with the R Bayesian Evidence Synthesis Tools , 2019, J. Stat. Softw..
[27] C. Lai,et al. The merits and problems of Neuropsychiatric Inventory as an assessment tool in people with dementia and other neurological disorders , 2014, Clinical interventions in aging.
[28] Roy W Jones,et al. Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials , 2007, Dementia and Geriatric Cognitive Disorders.
[29] Tim Friede,et al. Bounds for the weight of external data in shrinkage estimation , 2020, Biometrical journal. Biometrische Zeitschrift.
[30] S J Pocock,et al. The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.
[31] Pierre N Tariot,et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.
[32] J. Ibrahim,et al. Power prior distributions for regression models , 2000 .
[33] P. Tariot,et al. A 24-week Randomized, Controlled Trial of Memantine in Patients With Moderate-to-severe Alzheimer Disease , 2007, Alzheimer disease and associated disorders.
[34] Carlos Barrios,et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.